Drugs / CLDN6 CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04503278 | Sep 2020 → Aug 2028 expected | cancer | BioNTech Cell & Gene Therapies GmbH | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06940804 | Jul 2025 → Jun 2042 | extragonadal germ cell tumor, testicular germ cell tumor | BioNTech SE | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-10-23 | BioNTech SE | Results BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023 biontech.com ↗
The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac. |
| 2023-10-16 | BioNTech SE | Results BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023 biontech.com ↗ |
| 2022-09-09 | BioNTech SE | Results BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO biontech.com ↗
The results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels. |
| 2022-06-23 | BioNTech SE | Regulatory BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer biontech.com ↗
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to BioNTech’s fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors. |
| 2022-04-11 | BioNTech SE | Results BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR biontech.com ↗
The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLDN6 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04503278 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR) T cells” PMID 37872225 ↗ Oct 2023 |
| Route | Intravenous | “administered as an intravenous (i.v.) infusion.” NCT04503278 ↗ |
| Target | CLDN6 | “CAR T cells targeting the CLDN6” PMID 37872225 ↗ Oct 2023 |